Rights Issue December 2024
SynAct initiates filing process for Phase 2b ADVANCE study with resomelagon
SynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis
March 11, 2024
Resolving Inflammation Without Immunosuppression
Most available treatments used to treat inflammation suppress the immune system which can lead to a heightened risk of serious safety issues. Inflammation resolution strategies seek to provide both anti-inflammatory and pro-resolving activity without suppressing the immune system.
Harnessing the Melanocortin System to Resolve Inflammation
SynAct harnesses the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms to resolve excessive inflammation safely without suppressing the immune system’s ability to respond to new infections or injuries.
Resomelagon (AP1189)
An Oral Selective Melanocortin Agonist
Our lead drug candidate resomelagon (AP1189) is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve inflammation. Resomelagon (AP1189) is being evaluated in rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN) and respiratory insufficiency caused by viruses like COVID-19.
-
February 20, 2025 RegulatorySynAct’s Nomination Committee proposes Jeppe Ragnar Andersen to the Board
-
February 18, 2025 RegulatorySynAct Pharma Year-end Report 2024
-
January 31, 2025 RegulatoryChange in number of shares and votes in SynAct Pharma AB
The interim report for Q4 2024 was published on February 18, 2025, at 07.30 CEST.
A MESSAGE FROM OUR CEO
”We are very grateful to those helping with the ADVANCE trial and to all of our shareholders who continue to give us their support.”